Hunterase

BIOLOGICAL2 trials

Sponsors

Green Cross Corporation, GC Biopharma Corp

Conditions

GC1111Hunter SyndromeHunter Syndrome (MPS II)HunteraseMPS II

Phase 3

Safety and Efficacy of Hunterase

CompletedNCT01645189

Green Cross CorporationHunter Syndrome

Start: 2012-07-31End: 2013-09-30Updated: 2014-07-08

An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)

CompletedNCT07344376

GC Biopharma CorpGC1111, Hunterase, Hunter Syndrome +2

Start: 2018-05-23End: 2022-12-30Updated: 2026-01-15

Related Papers

Sustained clinical benefit of idursulfase beta in mucopolysaccharidosis II: two-year experience from a phase 3 extension study including patients switched from idursulfase

Orphanet Journal of Rare Diseases2026-07-09

Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.

2014-08-3016 citations